Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma

被引：14

作者：

Abeykoon, Jithma P. ^{[1
]}

Vaxman, Julia ^{[1
]}

Patel, Sanjay V. ^{[2
]}

Kumar, Shaji ^{[1
]}

Malave, Gabriella C. ^{[1
]}

Young, Kimberly S. ^{[1
]}

Ailawadhi, Sikander ^{[3
]}

Larsen, Jeremy T. ^{[4
]}

Dispenzieri, Angela ^{[1
]}

Muchtar, Eli ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Kourelis, Taxiarchis ^{[1
]}

Leung, Nelson ^{[1
]}

Warsame, Rahma ^{[1
]}

Go, Ronald S. ^{[1
]}

Bergsagel, Leif ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

Gertz, Morie A. ^{[1
]}

Kapoor, Prashant ^{[1
]}

机构：

[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA

[2] Mayo Clin, Dept Ophthalmol, Rochester, MN USA

[3] Mayo Clin, Div Hematol & Oncol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Div Hematol, Scottsdale, AZ USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 01期

关键词：

antibody-drug conjugate; B-cell maturation antigen; monoclonal gammopathy; ANTIBODY; DRUG;

D O I：

10.1111/bjh.18298

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Belantamab mafodotin (BLMF) is a B-cell maturation antigen-directed antibody-drug conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF-induced ocular toxicity on patient outcomes is unknown. We studied a cohort of 38 consecutively seen patients treated with BLMF outside of trials. Of those, 75% experienced ocular toxicity, with 69% developing keratopathy. Among patients requiring ocular toxicity-related permanent BLMF discontinuation (14%) or dose reduction (11%), 70% had progression of MM within a median of 3 months (95% confidence interval: 0.2-not reached) following BLMF interruption or dose reduction. Ocular toxicity is a major deterrent to the continuous use of BLMF in routine clinical practice. Measures to successfully prevent and mitigate ocular toxicity should be developed to achieve the full potential of this agent.

引用

页码：95 / 99

页数：5

共 50 条

[31] Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over
Condorelli, Annalisa
Garibaldi, Bruno
Gagliano, Caterina
Romano, Alessandra
Del Fabro, Vittorio
Parrinello, Nunziatina Laura
Longo, Antonio
Cosentino, Sebastiano
Di Raimondo, Francesco
Conticello, Concetta
ACTA HAEMATOLOGICA, 2021,
[32] Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
Neupane, Karun
Wahab, Ahsan
Masood, Adeel
Faraz, Tehniat
Bahram, Saman
Ehsan, Hamid
Hannan, Abdul
Anwer, Faiz
JOURNAL OF BLOOD MEDICINE, 2021, 12 : 529 - 550
[33] Prevention of Ocular Toxicity Using Protective Contact Lenses in Multiple Myeloma Patients Receiving Belantamab Mafodotin, Pomalidomide and Dexamethasone: A SubStudy of the Cmrg-007 Trial
Louzada, Martha L.
Reece, Donna E.
McCurdy, Arleigh
Kotb, Rami
Othman, Ibraheem
Mian, Hira
Lin, Toni
Chu, Michael P.
White, Darrell
Parkin, Stephen
Gul, Engin
Khan, Aniba
Trudel, Suzanne
BLOOD, 2023, 142
[34] Ocular adverse events and functional impact in transplant ineligible, newly diagnosed multiple myeloma patients treated with belantamab mafodotin, lenalidomide and dexamethasone in BelaRd trial
Terpos, Evangelos
Ntanasis-Stathopoulos, Ioannis
Gavriatopoulou, Maria
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Spiliopoulou, Vassiliki
Syrigou, Rodanthi
Eleutherakis-Papaiakovou, Evangelos
Gkolfinopoulos, Stavros
Manousou, Kyriaki
Kastritis, Efstathios
Dimopoulos, Meletios
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S102 - S103
[35] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
Hultcrantz, Malin
Orozco, Jennifer
Peterson, Tim J.
Derkach, Andriy
Hassoun, Hani
Korde, Neha
Lu, Sydney X.
Mailankody, Sham
Patel, Dhwani
Shah, Urvi A.
Tan, Carlyn
Maclachlan, Kylee H.
Chung, David J.
Landau, Heather J.
Shah, Gunjan L.
Lahoud, Oscar B.
Scordo, Michael
Landgren, Ola
Giralt, Sergio
Lesokhin, Alexander
BLOOD, 2021, 138
[36] Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
Shah, Anshul
Tosh, Jonathan C.
Ambavane, Apoorva
Nikolaou, Andreas
Hogea, Cosmina
Samyshkin, Yevgeniy
Gorsh, Boris
Maiese, Eric M.
Wang, Feng
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 789 - 800
[37] Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3
Hungria, Vania T. M.
Weisel, Katja
Radinoff, Atanas
Delimpasi, Sosana
Mikala, Gabor
Masszi, Tamas
Li, Jian
Capra, Marcelo
Maiolino, Angelo
Pappa, Vasiliki
Chraniuk, Dominik
Osipov, Iurii
Leleu, Xavier
Low, Michael
Matsumoto, Morio
Li, Mary
Sule, Neal
Polinkovsky, Margaret
Davis, Randy
Bright, Shelley
McKeown, Astrid
Opalinska, Joanna
Dimopoulos, Meletios Athanasios
BLOOD, 2023, 142
[38] Multiple Myeloma Belantamab Mafodotin opens up new Treatment Perspective
Sankawa, Yuri
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (7-8) : 427 - 428
[39] Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma
Zhang, Yifei
Godara, Amandeep
Pan, Stacey
Toskic, Denis
Mann, Hashim
Sborov, Douglas
Comenzo, Raymond
Kansagra, Ankit
ANNALS OF HEMATOLOGY, 2022, 101 (09) : 2119 - 2121
[40] Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
Offidani, Massimo
Corvatta, Laura
More, Sonia
Olivieri, Attilio
DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2401 - 2415

← 1 2 3 4 5 →